Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of remibrutinib in secondary progressive multiple sclerosis
MOH_2025-11-05_015433Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Remibrutinib with Placebo (2 arms). Started Sep 2025; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on MOH_2025-11-05_015433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-05_015433.